Meet Our Team
KENNETH KASHKIN, M.D.
Co-Founder |
MIKE SECKLER
Advisor |
JANE KIERNAN
Co-Founder |
|
Kenneth Kashkin trained and served on the faculties of the UCLA and Yale University Schools of Medicine. Ken's career spans more than two decades as a healthcare business senior executive and biotechnology investor. A recognized leader in the financing and management of research, development and commercialization organizations, he led divisions of Bayer, Abbott, Knoll/BASF Pharma, Ferring, Baxter, and was CEO and President of Catholic Health Initiatives Institute for Research and Innovation. Ken led management teams at several biotech companies, including Nova, Genaissance, and Chromocell. He identifies and invests in breakthrough innovations as a member of the New York City based MidAtlantic BioAngels (MABA).
READ MORE |
Mike Seckler has served as a Biotech and Pharmaceutical executive with over fifteen years’ leadership experience at the VP and General Manager level across diverse environments from start-up to large multi-national companies. Mike has developed an impressive track record in leading complex high performing teams with limited resources in the US, Canada, and Europe. Mike's commercialization responsibilities oversaw business development, new product development and marketing - including pre-launch and launch in diverse therapeutic areas: Fertility, Oncology, Cardiovascular, and Gastroenterology. Most recently Mike co-founded FerGene—a joint venture with $400mn investment from Blackstone and $170mn investment from Ferring.
READ MORE |
Jane Kiernan is an experienced public company Board Director with Axonics Modulation Technologies, Endologix, American Medical Systems and was CEO and President of Salter Labs, a privately held medical device company with revenues of $85 million. Ms. Kiernan has more than 30 years of executive and management leadership with both public and private companies in the health care field. She has excellent financial expertise to support her strengths in strategy, mergers & acquisitions, and scaling for global growth.
READ MORE |